Neisseria meningitidis lipopolysaccharides in human pathology.
Neisseria meningitidis causes meningitis, fulminant septicemia or mild meningococcemia attacking mainly children and young adults. Lipopolysaccharides (LPS) consist of a symmetrical hexa-acyl lipid A and a short oligosaccharide chain and are classified in 11 immunotypes. Lipid A is the primary toxic component of N. meningitidis. LPS levels in plasma and cerebrospinal fluid as determined by Limulus amebocyte lysate (LAL) assay are quantitatively closely associated with inflammatory mediators, clinical symptoms, and outcome. Patients with persistent septic shock, multiple organ failure, and severe coagulopathy reveal extraordinarily high levels of LPS in plasma. The cytokine production is compartmentalized to either the circulation or to the subarachnoid space. Mortality related to shock increases from 0% to > 80% with a 10-fold increase of plasma LPS from 10 to 100 endotoxin units/ml. Hemorrhagic skin lesions and thrombosis are caused by up-regulation of tissue factor which induces coagulation, and by inhibition of fibrinolysis by plasminogen activator inhibitor 1 (PAI-1). Effective antibiotic treatment results in a rapid decline of plasma LPS (half-life 1-3 h) and cytokines, and reduced generation of thrombin, and PAI-1. Early antibiotic treatment is mandatory. Three intervention trials to block lipid A have not significantly reduced the mortality of meningococcal septicemia.
Brandtzaeg
P
P
Departments of Pediatrics, Ullevål University Hospital, University of Oslo, Oslo, Norway. petter.brandtzaeg@ioks.uio.no
Bjerre
A
A
Øvstebø
R
R
Brusletto
B
B
Joø
G B
GB
Kierulf
P
P
D016207:Cytokines / Q000097:blood; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D008070:Lipopolysaccharides / Q000097:blood / Q000737:chemistry / Q000276:immunology / Q000633:toxicity; D008585:Meningitis, Meningococcal / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D008589:Meningococcal Infections / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D009345:Neisseria meningitidis / Q000472:pathogenicity*; D010400:Penicillin G / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000276:immunology; D011110:Polymorphism, Genetic; D018805:Sepsis / Q000175:diagnosis
D016207:Cytokines; D008070:Lipopolysaccharides; D010406:Penicillins; D017395:Plasminogen Activator Inhibitor 1; D010400:Penicillin G